FDA approves Alzheimer’s drug, pushing drugmaker’s shares up

The US Food and Drug Administration approved on January 6 Esai and Biogen’s lecanemab, the second-ever treatment for Alzheimer’s disease intended to tackle the root of the condition and slow cognitive decline.

Source: https://businessmirror.com.ph/2023/01/14/fda-approves-alzheimers-drug-pushing-drugmakers-shares-up/